Смотреть эффекты (1980) в Full HD качестве ОНЛАЙН

Дата: 28.12.2017

эффекты (1980)

Discoloration of the skin or urine hair loss or thinning of the hair swelling or inflammation of the mouth For Healthcare Professionals Applies to sulfasalazine: Less common side effects included urticaria, fever, Heinz body anemia, hemolytic anemia, and cyanosis.

The use of enteric-coated preparations may decrease gastrointestinal side effects. Abdominal pain, diarrhea, stomatitis Frequency not reported: Impaired folic acid absorption, impaired digoxin absorption, neutropenic enterocolitis, hemorrhagic colitis, bloody diarrhea, necrotizing pancreatitis Postmarketing reports: Pseudomembranous colitis, pancreatitis, worsening ulcerative colitis, parotitis[ Ref ] Nervous system Transverse myelitis developed in 1 patient after receiving sulfasalazine for 2 years.

All symptoms resolved within 2 months after discontinuing sulfasalazine. Dizziness, taste disorders, tinnitus Uncommon 0. Convulsions, vertigo Frequency not reported: Meningitis, neuropathy, transverse myelitis, transient lesions of the posterior spinal column, cauda equina syndrome, Guillain-Barre syndrome, hearing loss, drowsiness, neurotoxicity, dysphasia, acute encephalopathy, monoparesis, cerebrospinal fluid abnormalities, altered taste, peripheral neuritis Postmarketing reports: Aseptic meningitis, ataxia, encephalopathy, peripheral neuropathy, smell disorders[ Ref ] Metabolic Hypoglycemia has been reported rarely in patients using sulfonamides.

Folate deficiency, loss of appetite Genitourinary Diuresis has been reported rarely in patients using sulfonamides. Infertility appeared to be reversible upon drug discontinuation. Proteinuria Rare less than 0. Impotence, diuresis Frequency not reported: Decreased motility, abnormal sperm penetration sometimes resulted in infertility , urinary tract infections, urine discoloration Postmarketing reports: Hematuria, crystalluria[ Ref ] Dermatologic Angioedema was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.

The risk of Stevens-Johnson syndrome or toxic epidermal necrolysis increased largely with the use of sulfonamides; however, these phenomena were rare as a whole. Pruritus, urticaria Uncommon 0. Alopecia Frequency not reported: In most cases of sulfasalazine-induced SLE, patients received the drug for greater than 1 year. Patients most commonly developed arthralgias and pleuritic chest pain. Symptoms typically resolved over several weeks to several months. At least 1 case of Kawasaki-like syndrome with hepatic function changes was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.

Drug-induced systemic lupus erythematosus SLE Postmarketing reports: Abnormal liver function tests Uncommon 0. Elevated liver enzymes Frequency not reported: Hepatic necrosis Postmarketing reports: Associated rash usually progressed to desquamation. Liver biopsy has shown necrosis and infiltration with moderate number of inflammatory cells. Noncaseating granulomas have also been seen. Hepatitis generally resolved over several weeks after therapy discontinuation, although some patients progressed to fulminant hepatic failure.

Hepatitis has been reported in patients with sulfasalazine hypersensitivity. Some of these cases were fatal. Side effects listed as postmarketing reports were reported during postmarketing experience with the use of products containing or metabolized to mesalamine.

Patients often presented with fever and sore throat. A few also presented with a rash. Bone marrow hypoplasia or aplasia was usually confined to the myeloid series, but may be accompanied by erythroid hypoplasia and marrow plasmacytosis.

In one review of 62 cases of sulfasalazine-induced agranulocytosis, 6. Recovery of granulocytes was generally seen within 1 to 2 weeks after drug discontinuation, and leukocyte counts and differential returned to normal in 1 to 3 weeks. Some cases of agranulocytosis were treated with colony stimulating factor, which appeared to increase the time to recovery.

Hemolytic anemia, Heinz body anemia, leukopenia Uncommon 0. Thrombocytopenia Frequency not reported: Red cell aplasia, congenital neutropenia, myelodysplastic syndrome Postmarketing reports: Dyspnea Frequency not reported: Oropharyngeal pain, fibrosing alveolitis, eosinophilic infiltration, interstitial lung disease[ Ref ] Patients often presented after several weeks or months of therapy with fever, malaise, shortness of breath, and nonproductive cough.

Eosinophilic infiltrates have been seen. Respiratory changes generally resolved over a few weeks, however, fatal reactions involving fibrosing alveolitis have been reported. Vasculitis Frequency not reported: Depression Frequency not reported: Confusion, vivid dreams Postmarketing reports: Arthralgia Frequency not reported: Facial edema Frequency not reported: Conjunctival and scleral injection Frequency not reported: Diplopia, blurred vision, corneal damage[ Ref ] Hypersensitivity The following side effects have been reported as hypersensitivity reactions: Anaphylaxis was reported during postmarketing experience with the use of products containing or metabolized to mesalamine.

Hypersensitivity reactions, drug-induced rash, lupus erythematosus-like syndrome, anaphylactoid reactions Postmarketing reports: Anaphylaxis, serum sickness[ Ref ] Renal Frequency not reported: Toxic nephrosis with oliguria and anuria, nephritis, hemolytic uremic syndrome, bilateral renal calculi composed of acetylsulfapyridine, proteinase 3-ANCA positive necrotizing glomerulonephritis Postmarketing reports: Nephrolithiasis, nephrotic syndrome, interstitial nephritis[ Ref ] At least 1 patient developed bilateral renal calculi composed of acetylsulfapyridine, a metabolite of sulfasalazine.

Goiter production[ Ref ] Goiter production has been reported rarely in patients using sulfonamides. Marcus RW "Sulfasalazine induced taste disturbances. Nielsen OH "Sulfasalazine intolerance.

A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Adverse effects and desensitization. Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Pharmacology, clinical use, toxicity, and related new drug development. Siam AR, Hammoudeh M "Sulfasalazine induced systemic lupus erythematosus in a patient with rheumatoid arthritis.

Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine. Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration. Sullivan SN "Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate. Baillie J "Sulfasalazine and pulmonary infiltrates. Always consult your doctor or healthcare specialist for medical advice.

You may also report side effects to the FDA.